{
    "clinical_study": {
        "@rank": "102603", 
        "arm_group": {
            "arm_group_label": "Renal Cell Carcinoma Tumor Tissue", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The primary objective is to evaluate methods for AGS-003 production from surgical (stage I)\n      and metastatic biopsy (stage II) Renal Cell Carcinoma (RCC) specimens using core needle\n      biopsy in subjects with RCC.  Specifically, this study will evaluate the feasibility of RNA\n      amplification from total tumor RNA isolated from tissues obtained by core needle tumor\n      biopsy."
        }, 
        "brief_title": "RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)", 
        "condition": "Metastatic Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        A subject with metastatic RCC, who in the opinion of the treating physician, is a\n        potential candidate for inclusion in this study if all of the following criteria apply:\n\n          1. 18 years of age or older.\n\n          2. Histologically confirmed RCC.\n\n          3. Metastatic disease in the opinion of the investigator.\n\n          4. Availability of either:\n\n               -  Nephrectomy or other surgically removed tissue (Stage I); or,\n\n               -  Metastatic RCC biopsy tissue utilizing needle or core biopsy procedures (Stage\n                  II).\n\n          5. \u22654 biopsy specimens available from BRPC.\n\n               -  Subjects who are having a surgical procedure (i.e. metastasectomy, nephrectomy)\n                  will have these core biopsies obtained from the surgical specimen, per the BRPC\n                  protocol.\n\n          6. Not currently being treated with systemic therapy.\n\n        Exclusion Criteria:\n\n          1. Tumor tissue is committed to other use or inadequate for RNA analysis.\n\n          2. Insufficient tissue is collected in the BRPC."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02026960", 
            "org_study_id": "Pro00047147"
        }, 
        "intervention": {
            "arm_group_label": "Renal Cell Carcinoma Tumor Tissue", 
            "intervention_name": "RNA extraction and amplification from biopsy specimens", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 31, 2014", 
        "location": {
            "contact": {
                "email": "michael.goodin@dm.duke.edu", 
                "last_name": "Michael Goodin", 
                "phone": "919-668-8375"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "investigator": {
                "last_name": "Michael Harrison, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Michael Harrison, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To Determine the success rate for tumor RNA isolation and amplification create a minimum of 10 doses of AGS-003, as defined by a minimum concentration of \u226584 \u00b5g/\u00b5L in typically greater than 150 \u00b5L final volume RNA. (Tissue obtained at time of surgery or biopsy depending on stage)", 
            "measure": "Success rate for tumor RNA isolation and amplification", 
            "safety_issue": "No", 
            "time_frame": "At time of surgery or during biopsy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02026960"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Argos Therapeutics", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}